tbuckley/cabot-search huggingface dataset:
MECHANISMS OF ANTERIOR CRUCIATE LIGAMENT INJURIES IN VOLLEYBALL
Authors: Yukiko Karita, Yuka Kimura, Yuji Yamamoto, Takuya Naraoka, Shizuka Sasaki, Kazutomo Miura, Eiichi Tsuda, Yasuyuki Ishibashi
Journal: British Journal of Sports Medicine (2017)

Background Knee injuries were common in volleyball players, and ACL injury is a serious injury for athletes. Objective The purpose of this study was to investigate the mechanism of ACL injury in volleyball players using a questionnaire. Design Research study using a questionnaire. Setting Volleyball players who had ACL reconstruction at our institution. Patients Twenty-five females and 1 male (mean age; 24.6±11.0 years-old) volleyball players who ruptured their ACL during volleyball and underwent ACL reconstruction. Assessment of Risk Factors They were asked about their position, dominant hand defined as the spiking hand, side of injury, event during which the injury occurred (game or practice), the circumstance of injury (the situation in which the injury occurred, the specific motion at the time of injury) and player position and court location where the injury occurred. Results There were 19 wing spikers (left 13, right 6). Twenty-four players were right-handed and 2 players were left-handed, and 23 players injured the knees opposite to dominant hand. The 65.4% of injuries were prevalent during game. Twenty players (76.9%) were injured during spiking. Twenty-one players (80.8%) receive injured during landing, and 16 of them injured with single-leg landing after spiking. Most of ACL injuries (84.6%) occurred in front of the attack line near the net. Conclusions Single leg landing after spiking close to the net was the most common cause of injury, and most of wing spikers injured the knee opposite to their dominant hand. It suggests that wing spikers need to consider prevention strategies focusing on spiking movement.
A phase 3 study of alpelisib (ALP) plus fulvestrant (FUL) in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) ABC progressing on or after aromatase inhibitor (AI) therapy: SOLAR-1.
Authors: Hope S. Rugo, Fabrice Andre, Gabor Rubovszky, Bella Kaufman, Kenichi Inoue, Masato Takahashi, Satoru Shimizu, Eva M. Ciruelos, Mario Campone, Pier Franco Conte, Hiroji Iwata, Sibylle Loibl, Ingrid A. Mayer, Dejan Juric, Anne-Sophie Longin, David Mills, Celine Wilke, Dalila B. Sellami
Journal: Journal of Clinical Oncology (2017)

TPS1111 Background: Patients (pts) with HR+ breast cancer (BC) often havedysregulatedphosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway, which further leads to resistance to endocrine therapy (ET). In a phase 1 study, alpelisib (BYL719), a PI3Kα-specific inhibitor in combination with fulvestrant (FUL) has demonstrated antitumor activity in pts with estrogen receptor-positive, HER2– advanced BC (ABC) with PIK3CA-altered tumors. SOLAR-1 (NCT02437318) aims to assess the efficacy of ALP + FUL in PIK3CA-mutant and non-mutant tumors in HR+, HER2– ABC setting. Methods: SOLAR-1 is a phase 3, randomized, double-blind study conducted in men and postmenopausal women with HR+, HER2– ABC. Pts are randomly (1:1) allocated to oral alpelisib/placebo (300 mg qd) and intramuscular FUL (500 mg) until disease progression or treatment (tx) discontinuation. Stratification factors are presence of liver and/or lung metastases and prior use of CDK4/6 inhibitors. The eligibility criteria for the targeted BC patient population are shown in the Table. The primary endpoint is progression-free survival (PFS; RECIST v1.1; local assessment), while overall survival (OS) is a key secondary endpoint in the PIK3CA-mutant cohort. Other secondary endpoints are PFS and OS in the PIK3CA non-mutant cohort, the association between PFS and baseline PIK3CAstatus in ctDNA, overall response rate, clinical benefit rate, and safety. Recruitment of the planned 560 pts is currently ongoing. Clinical trial information: NCT02437318. [Table: see text]
A possible role of stem cells in nasal polyposis
Authors: L. Klimek, M. Koennecke, J. Mullol, P. W. Hellings, D.Y. Wang, W. Fokkens, P. Gevaert, B. Wollenberg
Journal: Allergy (2017)

Abstract Since its discovery, the understanding of stem/progenitor cells raised dramatically in the last decade. Their regenerative potential is important to develop new therapeutic applications, but the identification advanced much faster than our understanding of stem/progenitor cells. In nasal polyposis, little is known about stem cells/progenitor cells and their ability. However, the further characterization of stem cells/progenitor cells may provide new treatment options for combating nasal polyposis. This review highlights the knowledge of the current literature about stem cells/progenitor cells in nasal polyposis and how this may be exploited in the development of novel treatment strategies.
Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR–INDIAB population-based cross-sectional study
Authors: Ranjit Mohan Anjana, Mohan Deepa, Rajendra Pradeepa, Jagadish Mahanta, Kanwar Narain, Hiranya Kumar Das, Prabha Adhikari, Paturi Vishnupriya Rao, Banshi Saboo, Ajay Kumar, Anil Bhansali, Mary John, Rosang Luaia, Taranga Reang, Somorjit Ningombam, Lobsang Jampa, Richard O Budnah, Nirmal Elangovan, Radhakrishnan Subashini, Ulagamathesan Venkatesan, Ranjit Unnikrishnan, Ashok Kumar Das, Sri Venkata Madhu, Mohammed K Ali, Arvind Pandey, Rupinder Singh Dhaliwal, Tanvir Kaur, Soumya Swaminathan, Viswanathan Mohan, Ranjit Mohan Anjana, Mohan Deepa, Rajendra Pradeepa, Jagadish Mahanta, Kanwar Narain, Hiranya Kumar Das, Prabha Adhikari, Paturi Vishnupriya Rao, Banshi Saboo, Ajay Kumar, Anil Bhansali, Mary John, Rosang Luaia, Taranga Reang, Somorjit Ningombam, Lobsang Jampa, Richard O Budnah, Nirmal Elangovan, Radhakrishnan Subashini, Ulagamathesan Venkatesan, Ranjit Unnikrishnan, Ashok Kumar Das, Sri Venkata Madhu, Mohammed K Ali, Arvind Pandey, R S Dhaliwal, Tanvir Kaur, Soumya Swaminathan, Viswanathan Mohan, Vasudevan Sudha, Somasundaram Jaya Parvathi, Ramamoorthy Jayashri, Kaliaperumal Velmurugan, Prasanta Kumar Borah, Sathish B Rao, Jayendrasinh M. Padhiyar, Smita Sharma, Pachuau Lalramenga, Swapan Kumar Das, Th Bhubhonchandra Singh, Tao Kaki, Manoj Risbud Basaiawmoit, Deepak Kumar Shukla, Modugu Nageswara Rao, Prashant P Joshi, Vinay Kumar Dhandania, Shashank R Joshi, Chittaranjan Sakerlal Yajnik
Journal: The Lancet Diabetes & Endocrinology (2017)
A Randomised Assessment of Ganetespib Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results of the LI-1 Trial
Authors: Michael Dennis, Robert K Hills, Ian Thomas, Sunil Gupta, Nicki Panoskaltsis, Mhairi Copland, Alan K. Burnett, Nigel H Russell
Journal: Blood (2016)
Epidemiology and clinical profile of breast cancer in central Nepal: A single institutional experience.
Authors: Sachin Shakya
Journal: Journal of Clinical Oncology (2017)

e12008 Background: In this study, our objective was to determine the epidemiological and clinical profile of Breast Cancers. Different Literatures have highlighted the correlation between stage and age at diagnosis, size and age at diagnosis, correlations of different hormone receptor status with different age group etc. But precise documentation is lacking in Nepal. Methods: The study was conducted at department of Medical Oncology, Nepal Cancer Hospital and Research Centre from Dec 2014 to June 2016 and 183 patients diagnosed with breast cancer were enrolled. A retrospective cross-sectional study was conducted. Results: Prevalence of Breast Cancer was 5.59 %. Newar was the most affected ethnic group. The most frequent age group was 40 to 49. The most common symptom was mass in 80 % of patients. Stage II (49.1 %) was the most common stage at diagnosis. 83% patients had a tumour size of 2-5 cm with average size of 3.25 cm at presentation. Younger women with cancer had a strong correlation with ER-ve/PR-ve and Her-2/Neu +ve receptor status with P&lt;.005. Triple Negative receptor status was 32.87%. Her2/neu +ve receptor status cancer was 39.72%. Conclusions: Majority of patients presented with Stage IIa and IIIa disease breast cancer. Disease is more aggressive and diagnosed at a more advanced stage in younger women. Younger women had a strong correlation with ER-ve/PR-ve and her-2/neu +ve receptor. Recommendation for the Her-2/Neu receptor test should be done in every case of breast cancer. Triple negative status was lower in comparison to the previous studies which is favourable for hormonal antibody treatment implementation.
Abstract 136: Novel Disease Analysis Using Long QT Syndrome-Specific Induced Pluripotent Stem Cells
Authors: Toru Egashira, Shinsuke Yuasa, Keiichi Fukuda
Journal: Circulation Research (2012)

[Background] Although previous reports have indicated that long QT syndrome-specific iPS cells (LQTS-iPSCs)-derived cardiomyocytes recapitulated disease phenotypes, those patients were previously diagnosed with mutated channel profiles. In reality, most patients have no such specific information. To address whether iPSCs could be used for personalized disease characterization, we generated iPSCs from a sporadic LQTS patient with unknown disease cause. [Methods and Results] 1 We generated iPSCs from control (n = 2) and a patient with LQTS, and differentiated into cardiomyocytes through embryoid body (EB) formation. 2 Electrophysiological analysis of the LQTS-iPSCs-derived EBs using multi electrode array system revealed that the duration of the field potential (FPD) was markedly prolonged compared with the control (388.9 ± 44.3 msec vs 202.3 ± 16.3 msec, P&lt;0.01). 3 We tested several drugs affecting QT prolongation to clarify the electrophysiological properties. The IKr blocker E4031 significantly prolonged FPD (% change 1.21 ± 0.02, P&lt;0.01) and induced frequent severe arrhythmia, not only early-after depolarization (n = 8/16 vs n = 1/16) but also torsades de pointes-like arrhythmia, only in LQTS (n = 4/16 vs n = 0/16). The IKs blocker, chromanol 293B did not prolong FPD in LQTS but it significantly prolonged FPD in the control (% change 1.09 ± 0.04, NS vs 1.44 ± 0.07, P&lt;0.01), suggesting the involvement of IKs disturbance in the patient. Isoproterenol induced ventricular tachycardia-like arrhythmia only in LQTS, which was blocked by propranolol. These data strongly suggested a functional impairment in the patient’s IKs channel; genotype analysis for KCNQ1 gene revealed a novel heterozygous mutation, 1893delC. 4 Patch clamp analysis and immunostaining confirmed a dominant-negative role for 1893delC in IKs channel through a trafficking deficiency. [Conclusions] LQTS-iPSCs-derived cardiomyocytes recapitulated the disease phenotypes, and they can be utilized for identification of the disease cause and genotype. This study demonstrated that iPSCs could be useful to characterize the disease, drug responses, diagnosis and genotyping in patients with sporadic LQTS, which in turn may facilitate medical therapies in the clinical settings.
Independent confirmation of the strong early predictive value of modeled PSA clearance in prostate cancer patients treated by radical prostatectomy: Results of the prospective PSAMODEL study.
Authors: Denis Maillet, Alain Ruffion, Paul Perrin, Melanie Wilbaux, Emilie Henin, Gilles Freyer, Michel Tod, Benoit You
Journal: Journal of Clinical Oncology (2012)

e15182 Background: Early predictors of relapse after radical prostatectomy are needed. We previously showed that mathematical modeling of PSA kinetics provides a parameter, apparent PSA clearance (CLPSA), which may be a significant early predictor of biochemical relapse [1] (You et al; Prostate 2009;69:1325). Validation of these outcomes in an independent prospective study was warranted. Methods: As required by the initial study, four PSA values were prospectively measured during the first 50 days following radical prostatectomy in 119 patients with localized prostate cancer at our center. PSA values were centrally measured. The bi-compartment model previously reported in 2009 [1] was used to calculate patient CLPSA with NONMEM program. The predicted risk of biochemical relapse based on CLPSA cut-off previously defined (threshold at 0.048 [1]) was assessed using survival univariate and multivariate analyses. The primary endpoint was 3-year biochemical relapse free survival (3 y-bRFS). Results: The data from 119 patients treated with radical prostatectomy were analyzed. Among them 13 experienced a relapse after median 6.5 months. Despite large inter-individual variability, individual PSA decline profiles of patients were well fitted by the model. CLPSA categorized by the same cut-off previously described [1] was a significant predictor of 3 y-bRFS using log-rank test (97% vs 66%, p=0.009). Moreover it had independent significant predictive value when adjusted on other prognostic factors (D’Amico score) using multivariate Cox model (p&lt;0.05). Conclusions: This prospective PSAMODEL studyconfirms modeled CLPSA calculated during the first 50 days after radical prostactectomy is a strong independent reproducible early predictor of biochemical relapse. It may easily be calculated using 4 PSA values after surgery. The potential role of this factor in adjuvant treatment adjustment may be studied. [1] You et al; Prostate 2009;69:1325
Successful engraftment following reduced-intensity cord blood transplantation with fludarabine and oral busulfan for advanced hematologic diseases
Authors: T. Azuma, M. Kami, E. Kusumi, Y. Sato, Y. Miura, T. Komatsu
Journal: Journal of Clinical Oncology (2007)

7110 Background: Feasibility of reduced-intensity cord blood transplantation (RI-CBT) has been demonstrated in adult patients. Most researchers use preparative regimens containing total body irradiation (TBI) 2–4 Gy, while TBI causes considerable toxicities in elderly patients. We investigated the feasibility of RI-CBT using non-TBI regimen for the treatment of adult hematologic diseases. Methods: Nineteen patients (median age, 61, range, 38–74) with advanced hematological diseases were enrolled in this study. Fifteen patients had chemorefractory diseases at RI-CBT. Preparative regimen comprised fludarabine 180 mg/m 2 and oral busulfan 8 mg/kg. Graft-versus-host disease (GVHD) prophylaxis was tacrolimus. Engraftment was defined as an absolute neutrophil count &gt; 0.5 × 10E9/l. Primary graft failure was defined as the complete loss of donor-type hematopoiesis occurring without engraftment. Secondary graft failure was defined as the loss of donor-type hematopoiesis occurring after primary engraftment. Endpoint of this study was engraftment. Median follow-up of surviving patients was 24.7 months (range, 21.6–25.8). Results: All the patients tolerated the preparative regimen. Median dose of infused nuclear cells was 2.7x10E7/kg (range, 1.9–4.6). HLA disparity was found in 2/6 antigens (n=16) and 1/6 antigen (n=3). Eleven patients achieved engraftment at a median of day 18 (range, 9–30). Chimerism analysis was conducted in six of these eleven patients, and complete donor-type chimerism was documented within 30 days of transplant in five patients. Primary graft failure was diagnosed in two patients. The other six patients died without engraftment due to diffuse alveolar hemorrhage(n=1) and disease progression(n=5). No patients developed acute GVHD. Five of the 11 patients who achieved primary engraftment developed secondary graft failure. As of December 2006, four patients survived in complete remission with complete donor-type chimerism. Estimated 1-year overall survival rate was 21.1%. Conclusions: This study demonstrated the feasibility of RI-CBT using non-TBI regimen; however, high incidences of disease progression before engraftment and secondary graft failure were significant problems. No significant financial relationships to disclose.
The radiation doses to the heart and the left anterior descending coronary artery for various modes of radiation treatment of the breast cancer patients.
Authors: Elizaveta Maslyukova, Luiza Korytova, Anna Bondarenko, Razifa Zhabina, Oleg Korytov, Svetlana Odintsova
Journal: Journal of Clinical Oncology (2017)

e12092 Background: The comparison of the radiation load to the organs at risk for three modes of radiation treatment of the breast cancer patients. Methods: The research includes the dosimetric radiation treatment plans for the 20 breast cancer patients with the left-side localization. They all underwent a computed tomography (CT) scan in standard supine position in free-breathing (FB), supine position with Active Breathing Control (ABC) device in deep inspiratory breath hold, and prone position in free-breathing (PP). Three-dimensional treatment plans were made for all 3 CTs. The dose valuations for 3D-planning were carried out for three CT- series. For each mode of radiation, the doze-volume parameters of organs at risk were estimated. Results: For all cases the contoured heart volume varied from 477 см3 - 1056 см3, with medium volume 769 см3. The best marks such as V 25heart , medium doses to the heart and LAD, were achieved with on ABC methods (V 25heart 4,26%, D mean heart 3,13Gy, D meanLAD 13,8Gy) in comparison FB (V 25heart 9,49%, D mean heart 4,97Gy, D meanLAD 19,55Gy) and PP (V 25heart 12,8%, D mean heart 9,06Gy, D meanLAD 24,18 Gy) (V 25heart P = 0.00153, D mean heart : P =0,000; D mean LAD : P = 0.00088), when both the breast and the axillary nodes were included in the volume. The advantage of the dosimetric indexes for FB and ABC did not change while axillary and supraclavicular nodes were added to the radiation volume ABC (V 25heart 3,49%, D mean heart 3,08Gy, D meanLAD 13,88Gy) in comparison with FB methods (V 25heart 7,91%, D mean heart 4,99Gy, D meanLAD 19,89Gy) (V 25heart P = 0.00205, D mean heart : P =0,004; D mean LAD : P = 0.03). Conclusions: Radiation treatment in the position on the back with controlled delay of breath on inspiration height contributed to the statistically significant reduction of the heart volume exposed to more than 25 Gy (V 25heart ), mean dose to the heart and mean dose to LAD.
Inflammatory cell infiltration and resolution of kidney inflammation is orchestrated by the cold-shock protein Y-box binding protein-1
Authors: Anja Bernhardt, Alexander Fehr, Sabine Brandt, Saskia Jerchel, Tobias M. Ballhause, Lars Philipsen, Saskia Stolze, Robert Geffers, Honglei Weng, Klaus-Dieter Fischer, Berend Isermann, Monika C. Brunner-Weinzierl, Arvind Batra, Britta Siegmund, Cheng Zhu, Jonathan A. Lindquist, Peter R. Mertens
Journal: Kidney International (2017)
Radiation-induced CD4 and CD8 Τ-lymphocyte apoptosis analysis in patients with prostate adenocarcinoma overexposed to radiations (EPOPA).
Authors: Jean-Louis Merlin, Alexandra Rousseau, Guillaume Vogin, Didier Peiffert, Labib El Hajj, Mihai Levitchi, Jean-Marc Simon
Journal: Journal of Clinical Oncology (2014)

e20637 Background: Between 2000 and 2006, patients with prostate adenocarcinioma were accidentally overexposed to radiations in Epinal general hospital, France and constitutes the EPOPA (Epinal Patients Overexposed for a Prostate Adenocarcinoma) cohort. The total doses received by those patients were 8% to 54% higher than doses prescribed. Radiation-induced T-lymphocyte apoptosis (RILA) can predict differences in late toxicity between individuals. Methods: Between 2008 and 2010, 454 pts were included in EPOPA cohort. Digestive and urinary toxicity was graded per CTCAE v3. CD4 and CD8 RILA was analyzed using flow cytometry, according to Ozsahin et al (Clin Cancer Res 2005) from blood samples exposed to radiations (8 Gy). 245 EPOPA pts (54.0%) were included in the study. Results: 224 samples were analyzable (91.4%) for RILA. No significant difference was observed between the analyzed and the total patient populations regarding age, comorbidities, tobacco smoking, radical prostatectomy, and radiation dose. Median RILA values were 11.8 (mean 12.4, SD 4.6, range 4.1-31.9) and 15.3 (mean 15.9, SD 5.8, range 4.4-37.7) for CD4 and CD8 T-lymphocytes. Maximal digestive toxicity was grade 0-1 in 99 pts (44.2%), grade 2 in 88 pts (39.3%) and 3-4 in 37 pts (16.5%). Maximal urinary toxicity was grade 0-1 in 51 (29.0%) pts, grade 2 in 68 (38.6%) pts and 3-4 in 57 (32.4%) pts, in pts without prostatectomy (N=48); and grade 0-1 in 7 (14.6%) pts, grade 2 in 16 (33.3%) pts and grade 3-4 (52.1%) in 25 pts, for those irradiated after prostatectomy (N=176). No significant correlation between CD4 and CD8 RILA was observed with maximal digestive or urinary late toxicity. Conclusions: CD4 and CD8 RILA do not predict digestive or urinary late toxicity in patients overexposed to radiation. We hypothesize that the high doses delivered during overexposed radiation therapy should overcome cellular biological reparation pathways of normal tissues. (Funded by French Health Ministry and Institut National du Cancer (PHRC), EPOPA ClinicalTrials.gov number, NCT00773656).
Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long‐Term Clinical Trial Safety Data in Rheumatoid Arthritis
Authors: Mark C. Genovese, Joel M. Kremer, Ronald F. van Vollenhoven, Rieke Alten, Juan Jose Scali, Ariella Kelman, Sophie Dimonaco, Laura Brockwell
Journal: Arthritis & Rheumatology (2017)

To investigate liver enzyme abnormalities and hepatic adverse events (AEs) during long-term tocilizumab treatment for rheumatoid arthritis in clinical trials.
Inhibition of malignant glioma cell growth by a survivin mutant retrovirus
Authors: Achim Temme, Eric Herzig, Bernd Weigle, Hans K. Schackert, Peter Rieber
Journal: Cancer Research (2004)

4601  Glioblastoma multiforme (GBM) is a highly malignant brain tumour, which is resistant to conventional radiotherapy and chemotherapy. The median survival time of patients with GBM has remained approximately two years despite concerted efforts to improve therapy. In order to develop a new approach for the treatment of GBM we generated retroviral particles for transduction of glioma-derived cells with mutant survivin. Mutant forms of survivin, an inhibitor of apoptosis protein, have been reported to cause tumour cell apoptosis. We demonstrate here that retroviral delivery of a nonphosphorylable Thr34-Ala mutant of survivin (survivinT34A), resulted in cell cleavage defects, multinuclearity, growth inhibition and finally in apoptosis of glioblastoma target cells. The high degree of multinuclearity seen early after transduction was followed by apoptosis as detected by internucleosomal DNA fragmentation analysis and AnnexinV staining. Administration of z-Val-Ala-Asp(Me)-fluoromethyl ketone (zVAD-fmk) did not inhibit apoptosis suggesting a caspase-independent mechanism of cell death. Cell cleavage defects and apoptosis caused by the survivinT34A mutant protein were less prominent in survivin-expressing CD34+-hematopoetic stem cells and normal human lung fibroblasts. This suggests a specific effect of survivinT34A on glioblastoma cells, which might be exploited in the treatment of glioblastoma.